Matinas BioPharma Holdings, Inc. Logo

Matinas BioPharma Holdings, Inc.

Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.

MTNB | US

Overview

Corporate Details

ISIN(s):
US5768101058
LEI:
Country:
United States of America
Address:
1545 ROUTE 206 SOUTH, 7921 BEDMINSTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel products to address unmet medical needs. The company's core technology is its proprietary Lipid Nano-Crystal (LNC) platform, which enables the safe, oral, and intracellular delivery of small molecules, nucleic acids, and other therapeutics. Its lead product candidate, MAT2203, is an oral formulation of the anti-fungal drug amphotericin B. In addition to infectious diseases, Matinas is pursuing discovery programs using its LNC platform for applications in oncology and inflammation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Matinas BioPharma Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matinas BioPharma Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matinas BioPharma Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB

Talk to a Data Expert

Have a question? We'll get back to you promptly.